Amplia Therapeutics Ltd - Asset Resilience Ratio

Latest as of September 2025: 65.46%

Amplia Therapeutics Ltd (ATX) has an Asset Resilience Ratio of 65.46% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Amplia Therapeutics Ltd PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets

AU$29.16 Million

≈ $20.63 Million USD Cash + Short-term Investments

Total Assets

AU$44.54 Million

≈ $31.52 Million USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2017–2025)

This chart shows how Amplia Therapeutics Ltd's Asset Resilience Ratio has changed over time. See net asset quality index of Amplia Therapeutics Ltd to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Amplia Therapeutics Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ATX market cap.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	AU$29.16 Million	65.46%
Short-term Investments	AU$0.00	0%
Total Liquid Assets	AU$29.16 Million	65.46%

Asset Resilience Insights

Very High Liquidity: Amplia Therapeutics Ltd maintains exceptional liquid asset reserves at 65.46% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Amplia Therapeutics Ltd Industry Peers by Asset Resilience Ratio

Compare Amplia Therapeutics Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
CSL Ltd AU:CSL	Biotechnology	0.41%
BB Biotech AG SW:BION	Biotechnology	0.05%
Concord Biotech Limited NSE:CONCORDBIO	Biotechnology	18.00%
Pharming Group NV AS:PHARM	Biotechnology	7.13%
Innovita Biological Technology Co. Ltd. A SHG:688253	Biotechnology	65.12%
Wuhan Keqian Biology Co Ltd SHG:688526	Biotechnology	19.42%
Clarity Pharmaceuticals Ltd AU:CU6	Biotechnology	73.99%
Yantai Zhenghai Bio-Tech Co Ltd SHE:300653	Biotechnology	56.48%

Annual Asset Resilience Ratio for Amplia Therapeutics Ltd (2017–2025)

The table below shows the annual Asset Resilience Ratio data for Amplia Therapeutics Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-03-31	47.36%	AU$10.86 Million ≈ $7.69 Million	AU$22.94 Million ≈ $16.23 Million	+24.56pp
2024-03-31	22.80%	AU$3.39 Million ≈ $2.40 Million	AU$14.85 Million ≈ $10.50 Million	-19.92pp
2023-03-31	42.73%	AU$7.98 Million ≈ $5.65 Million	AU$18.68 Million ≈ $13.22 Million	-0.67pp
2022-03-31	43.39%	AU$10.62 Million ≈ $7.52 Million	AU$24.48 Million ≈ $17.32 Million	+26.40pp
2021-03-31	16.99%	AU$1.85 Million ≈ $1.31 Million	AU$10.88 Million ≈ $7.70 Million	+4.84pp
2020-03-31	12.16%	AU$1.11 Million ≈ $784.07K	AU$9.12 Million ≈ $6.45 Million	-1.35pp
2019-03-31	13.50%	AU$1.24 Million ≈ $878.02K	AU$9.19 Million ≈ $6.50 Million	-59.61pp
2018-03-31	73.11%	AU$1.93 Million ≈ $1.37 Million	AU$2.64 Million ≈ $1.87 Million	+10.17pp
2017-03-31	62.94%	AU$4.74 Million ≈ $3.36 Million	AU$7.54 Million ≈ $5.33 Million	--

pp = percentage points

About Amplia Therapeutics Ltd

AU:ATX Australia Biotechnology

Market Cap

$41.77 Million

AU$59.03 Million AUD

Market Cap Rank

#22600 Global

#822 in Australia

Share Price

AU$0.12

Change (1 day)

-4.17%

52-Week Range

AU$0.11 - AU$0.36

All Time High

AU$16.20